Cargando…
Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance
Dolutegravir (DTG), a second-generation integrase strand-transfer inhibitor (INSTI), is equivalent or superior to current non-nucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and first-generation INSTI-based antiretroviral regimens (ARVs). It has the potential to make...
Autores principales: | Ahmed, N, Flavell, S, Ferns, B, Frampton, D, Edwards, S G, Miller, R F, Grant, P, Nastouli, E, Gupta, R K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329901/ https://www.ncbi.nlm.nih.gov/pubmed/30648124 http://dx.doi.org/10.1093/ofid/ofy329 |
Ejemplares similares
-
Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
por: Nagami, Ellen H, et al.
Publicado: (2021) -
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014) -
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017) -
Transplant Drug Interactions and a Word of Caution for the HIV Provider. A Case Report
por: Hemmersbach-Miller, Marion, et al.
Publicado: (2018) -
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
por: Ciardi, Maria R, et al.
Publicado: (2018)